Harvard Net Receivables from 2010 to 2024

HBIO Stock  USD 2.20  0.01  0.46%   
Harvard Bioscience Net Receivables yearly trend continues to be very stable with very little volatility. Net Receivables is likely to grow to about 18.5 M this year. During the period from 2010 to 2024, Harvard Bioscience Net Receivables quarterly data regression pattern had sample variance of 18.2 T and median of  18,976,000. View All Fundamentals
 
Net Receivables  
First Reported
2000-12-31
Previous Quarter
12.5 M
Current Value
12.8 M
Quarterly Volatility
3.8 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Harvard Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Harvard Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.3 M, Interest Expense of 3.8 M or Total Revenue of 96.8 M, as well as many indicators such as Price To Sales Ratio of 1.72, Dividend Yield of 0.0022 or PTB Ratio of 4.65. Harvard financial statements analysis is a perfect complement when working with Harvard Bioscience Valuation or Volatility modules.
  
Check out the analysis of Harvard Bioscience Correlation against competitors.
To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.

Latest Harvard Bioscience's Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Harvard Bioscience over the last few years. It is Harvard Bioscience's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Harvard Bioscience's overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Harvard Net Receivables Regression Statistics

Arithmetic Mean18,288,044
Geometric Mean17,394,420
Coefficient Of Variation23.31
Mean Deviation2,604,063
Median18,976,000
Standard Deviation4,262,810
Sample Variance18.2T
Range17.4M
R-Value0.32
Mean Square Error17.5T
R-Squared0.10
Significance0.24
Slope306,405
Total Sum of Squares254.4T

Harvard Net Receivables History

202418.5 M
202316.1 M
202216.7 M
202121.8 M
202017.8 M
201920.7 M
201821.5 M

About Harvard Bioscience Financial Statements

Harvard Bioscience investors utilize fundamental indicators, such as Net Receivables, to predict how Harvard Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Receivables16.1 M18.5 M
When determining whether Harvard Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Harvard Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Harvard Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Harvard Bioscience Stock:
Check out the analysis of Harvard Bioscience Correlation against competitors.
To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.80)
Earnings Share
(0.33)
Revenue Per Share
2.258
Quarterly Revenue Growth
(0.13)
Return On Assets
(0.02)
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.